国产成人精品高清久久_好姑娘影视在线观看高清_99久久久久久久久_欧美涩涩网_久久国产精品91_9色网站

實驗室集團美國控股公司Laboratory Corporation of America? Holdings
美國LabCorp總部位于北卡羅萊納州的Burlington，1995年羅氏公司將其臨床實驗室同國家健康實驗室合并成立該公司。是美國第二大的獨立臨床實驗室公司。超過28,000名員工，一個先進的實驗室網絡和物流基礎設施，全球。我們的220,000客戶包括醫生辦公室，醫院，保健機構的管理，生物技術和制藥公司。 LabCorp加入每天超過40萬，每年檢驗樣品在1000萬和200萬細胞學手術病理標本過剩。我們繼續投資于創新內部和卓越的科學戰略，我們繼續對病人護理和質量的熱情。




LabCorp Clinical Trials 是其LabCorp集團旗下的一個重要部門。LabCorp Clinical Trials 可為世界各地的制藥企業和藥物研發公司根據其Pipeline提供及時、高效和創新性的實驗室檢測服務。LabCorp Clinical Trials 在比利時、中國、新加坡和美國設有四個全資擁有的中心實驗室，可提供全方位的中心實驗室檢測服務－包括一期至四期的臨床試驗、特殊項目檢測、新的生物標志物開發和驗證、新方法學的開發和伴隨診斷。
LabCorp Clinical Trials (Central Laboratory)


LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialized Centers of Excellence.

Recognized for our innovation, quality, and customer convenience, LabCorp delivers timely, accurate results for improved patient care.

With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp performs more than one million tests on approximately 400,000 samples each day. LabCorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients.

LabCorp operates a sophisticated laboratory network, with corporate headquarters in Burlington, NC, and over 28,000 employees worldwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under ticker symbol LH.

Many people think of LabCorp simply as the merger of Roche Biomedical Laboratories and National Health Laboratories in 1995. However, our roots extend back to 1905 when Hoffmann-La Roche began operations in the United States. Hoffmann-La Roche officially entered the lab business when it acquired the Kings County Research Laboratory in 1969. About the same time as Hoffmann-La Roche was purchasing Kings County Research Laboratory, Thomas Edward Powell III, and his twin brothers, Dr. James B. Powell and John Powell, were forming Biomedical Laboratories (later known as Biomedical Reference Laboratories) in a hospital basement in Burlington, NC. After a number of acquisitions, Hoffmann-La Roche acquired Biomedical Reference Laboratories in 1982. In 1983, Hoffmann-La Roche merged all of its laboratory companies into one company, which it called Roche Biomedical Laboratories (RBL).

Prior to the formation of RBL, Revlon, Inc. had also entered the laboratory business. After a few laboratory acquisitions, Revlon's laboratory business adopted the name National Health Laboratories Incorporated (NHL) in 1974, and NHL was operated as a wholly owned subsidiary of Revlon Holdings, Inc. NHL grew to $761 million in revenue by 1993. In 1994, NHL further broadened its laboratory testing capabilities by acquiring the sixth largest clinical lab in the US, Allied Clinical Health. By the mid 1990s NHL and RBL were two of the largest clinical, drug-screening, and paternity laboratories in the US.

In 1995, National Health Laboratories and Roche Biomedical Laboratories merged to become one of the largest clinical lab provider in the world. Initially led by Dr. James Powell, the new company – Laboratory Corporation of America – was headquartered in Burlington, NC. Over the last 10 years, LabCorp has continued to expand our esoteric and specialty laboratory testing capabilities by acquiring scientific leaders in the genomics, anatomic pathology, and personalized medicine arenas. In July 2000, LabCorp acquired Los Angeles-based National Genetics Institute, allowing LabCorp to gain NGI’s ultra-sensitive hepatitis C testing capability. In 2001, ViroMed, one of the leading laboratories in molecular microbial testing using real-time PCR platforms, became a part of LabCorp. LabCorp acquired Dynacare with locations in Washington, Tennessee, Wisconsin, and Canada in June 2002. In 2005, LabCorp acquired Esoterix, Inc. and its leading specialty labs – Colorado Coagulation, Endocrine Sciences, and Cytometry Associates.

In conjunction with our investments in expanding our esoteric testing capabilities, LabCorp continues to invest in building the most robust anatomic pathology capabilities in the world. LabCorp further strengthened its anatomic pathology capabilities by acquiring DIANON Systems in 2003 and US LABS in 2005. DIANON is distinguished for its capabilities in specific organ systems and clinical disciplines of uropathology, dermatopathology, and gastrointestinal pathology. US LABS’ extensive menu of esoteric oncology testing and expertise across multiple methodologies further balanced LabCorp’s anatomic pathology capabilities.

In 2006, LabCorp acquired Litholink, a premier provider for assisting physicians and their patients with outcomes management. The impact of these outcomes management programs in preventing disease recurrence or disease progression is impressive. More recently, LabCorp has expanded its clinical trials, personalized medicine, and companion diagnostic capabilities by purchasing Tandem Laboratories in 2008 and Monogram Biosciences in 2009. Tandem Laboratories is a leading bioanalytical and immunoanalytical contract research organization (CRO) supporting pharmaceutical and biotechnology companies with their discovery, preclinical, and clinical drug development programs. Monogram Biosciences is a recognized leader in the discovery and commercialization of products to guide and improve the treatment of HIV, cancer, and other serious diseases.

Today, LabCorp operates a sophisticated laboratory network and logistics infrastructure, with more than 28,000 employees worldwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. LabCorp accessions more than 400,000 samples per day and annually examines in excess of 10 million cytology and 2 million surgical pathology samples. We have continued to innovate internally and invest strategically in scientific excellence, and we continue to be passionate about patient care and quality.